Pulse Biosciences, Inc. (PLSE): who owns it and who trades it
As of Nov 16, 2026, PLSE insiders reported 7 open-market sales worth $2.9M and 6 purchases worth $13.5M in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kevin Patrick Danahy (Chief Commercial Officer), with $2.9M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Pulse Biosciences
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns PLSE
107 funds and institutions reported PLSE shares worth $321M at the end of Q2 2026, about 17% of the company. The largest holder is BlackRock, Inc. with 2.1%.
Funds and institutions (13F) 17%Everyone else 83%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 1.47M | 2.15% | $40.7M | +9% |
| Bank of America Corp | 1.45M | 2.12% | $40.1M | +67% |
| Vanguard Capital Management LLC | 788,640 | 1.16% | $21.9M | -3% |
| Portolan Capital Management, LLC | 753,333 | 1.10% | $20.9M | +3% |
| T. Rowe Price Associates | 748,638 | 1.10% | $20.8M | +4938% |
| Balyasny Asset Management L.P. | 718,103 | 1.05% | $19.9M | +171% |
| Citadel Advisors LLC | 626,514 | 0.92% | $17.4M | +341% |
| California State Teachers Retirement System | 567,883 | 0.83% | $20.5M | +2600% |
| Geode Capital Management, LLC | 536,276 | 0.79% | $14.9M | +9% |
| State Street Corp | 529,624 | 0.78% | $14.7M | +16% |
| Massachusetts Financial Services Co | 462,734 | 0.68% | $12.8M | No change |
| UBS Group AG | 275,669 | 0.40% | $7.6M | +712% |
| Griffin Asset Management, Inc. | 227,285 | 0.33% | $6.3M | +1% |
| Vanguard Portfolio Management LLC | 179,497 | 0.26% | $5M | +9% |
| Northern Trust Corp | 173,590 | 0.25% | $4.8M | -7% |
| Charles Schwab Investment Management Inc | 151,991 | 0.22% | $4.2M | +3% |
| Sixth Street Partners Management Company, L.P. | 151,991 | 0.22% | $4.2M | New |
| Vanguard Fiduciary Trust Co | 131,253 | 0.19% | $3.6M | +0% |
| Point72 Asset Management, L.P. | 106,457 | 0.16% | $3M | New |
| Norges Bank | 105,647 | 0.15% | $2.9M | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, PLSE insiders reported $13.5M of open-market purchases and $2.9M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Liane Rae Teplitsky | Chief Operating Officer | Purchase | 1,001 | $49.95 | $50K | Form 4 |
| Aug 31, 2026 | Liane Rae Teplitsky | Chief Operating Officer | Purchase | 1,024 | $48.80 | $50K | Form 4 |
| Aug 28, 2026 | Liane Rae Teplitsky | Chief Operating Officer | Purchase | 1,034 | $48.35 | $50K | Form 4 |
| Aug 26, 2026 | Liane Rae Teplitsky | Chief Operating Officer | Purchase | 1,036 | $48.24 | $50K | Form 4 |
| May 11, 2026 | Robert W Duggan | Director | Purchase | 660,233 | $19.69 | $13M | Form 4 |
| May 11, 2026 | Paul A Laviolette | CEO | Purchase | 15,000 | $19.69 | $295K | Form 4 |
| Feb 18, 2026 | Kevin Patrick Danahy | Chief Commercial Officer | Sale plan | 5,000 | $23.64 | $118K | Form 4 |
| Feb 17, 2026 | Kevin Patrick Danahy | Chief Commercial Officer | Sale plan | 20,000 | $23.63 | $473K | Form 4 |
| Feb 13, 2026 | Kevin Patrick Danahy | Chief Commercial Officer | Sale plan | 20,000 | $23.53 | $471K | Form 4 |
| Feb 12, 2026 | Kevin Patrick Danahy | Chief Commercial Officer | Sale plan | 20,000 | $23.37 | $467K | Form 4 |
| Feb 11, 2026 | Kevin Patrick Danahy | Chief Commercial Officer | Sale plan | 20,000 | $25.20 | $504K | Form 4 |
| Feb 10, 2026 | Kevin Patrick Danahy | Chief Commercial Officer | Sale plan | 20,000 | $23.52 | $470K | Form 4 |
| Feb 9, 2026 | Kevin Patrick Danahy | Chief Commercial Officer | Sale plan | 20,000 | $21.45 | $429K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Robert W Duggan | Director, 10% owner | $13M | – | May 11, 2026 |
| Kevin Patrick Danahy | Chief Commercial Officer | – | $2.9M | Feb 18, 2026 |
| Paul A Laviolette | Chief Executive Officer, Director | $295K | – | May 11, 2026 |
| Liane Rae Teplitsky | Chief Operating Officer | $200K | – | Sep 1, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
PLSE short interest
Low short interest. 4.1% of PLSE shares are sold short: about 1 share in 25. Over the last 12 reports the number of shares short went down 10%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.90M PLSE shares were sold short, 4.1% of the shares outstanding, down 3.5% from the report before. At the average daily volume of 351,715 shares, buying them all back would take about 8.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.90M | 4.07% | -3% | 351,715 | 8.2 |
| Oct 15, 2026 | 3.00M | 4.21% | -9% | 417,437 | 7.2 |
| Sep 30, 2026 | 3.31M | 4.64% | +6% | 590,533 | 5.6 |
| Sep 15, 2026 | 3.14M | 4.40% | +1% | 806,128 | 3.9 |
| Aug 31, 2026 | 3.12M | 4.38% | +13% | 392,846 | 7.9 |
| Aug 14, 2026 | 2.77M | 3.88% | -7% | 433,390 | 6.4 |
| Jul 31, 2026 | 2.98M | 4.18% | +3% | 426,187 | 7.0 |
| Jul 15, 2026 | 2.89M | 4.24% | +1% | 248,703 | 11.6 |
| Jun 30, 2026 | 2.86M | 4.19% | +1% | 433,595 | 6.6 |
| Jun 15, 2026 | 2.82M | 4.13% | -9% | 325,917 | 8.7 |
| May 29, 2026 | 3.09M | 4.52% | -4% | 294,877 | 10.5 |
| May 15, 2026 | 3.22M | 4.72% | +10% | 463,584 | 6.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Pulse Biosciences company events
Pulse Biosciences filed 32 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 6, 2026.
- Nov 6, 2026AnnouncementPulse Biosciences, Inc. announced interim six-month results from its PRECISE-BTN clinical study. Filing
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 14, 2026AnnouncementPulse Biosciences, Inc. announced entering into certain agreements with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida, and its affiliates, which together form a commercial and clinical partnership between them to explore the clinical utility of the Company's… Filing
- Oct 7, 2026AnnouncementPulse Biosciences, Inc. announced that it had achieved its enrollment target of 164 evaluable patients in its NANOPULSE-AF clinical study evaluating the Company’s nPulse™ Cardiac Catheter System for the treatment of atrial fibrillation. Filing
- Sep 15, 2026AgreementPulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC as sales agent, pursuant to which the Company may offer and sell, from time to time, through Mizuho, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering… Filing
- Sep 15, 2026AnnouncementPulse Biosciences, Inc. announced completion of patient enrollment in its PRECISE-BTN clinical study evaluating the Company’s nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules. Filing
- Aug 6, 2026AgreementPulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC as sales agent, pursuant to which the Company may offer and sell, from time to time, through Mizuho shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 29, 2026AnnouncementPulse Biosciences, Inc. announced surpassing the enrollment midpoint of its NANOPULSE-AF clinical study, a prospective, multicenter, pivotal, clinical investigation currently evaluating the Company’s nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal… Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- Jun 10, 2026AnnouncementPulse Biosciences, Inc. issued a press release announcing that it will deliver an irrevocable election to redeem the outstanding common stock warrants issued on July 3, 2024 in connection with the Company’s rights offering pursuant to its Registration Statement on Form S-3, as amended (File No.… Filing
- May 6, 2026AnnouncementThe Board of Directors of Pulse Biosciences, Inc. approved resolutions permitting TD Securities (USA) LLC, as sales agent, to sell Company common stock to one or more Company affiliates pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and between TD Cowen and the… Filing
- May 4, 2026AnnouncementPulse Biosciences, Inc. announced accelerated enrollment timelines in its NANOPULSE-AF clinical trial. Filing
- Apr 27, 2026AnnouncementShared information with investors. Filing
- Apr 16, 2026AnnouncementShared information with investors. Filing
- Apr 9, 2026LeadershipChief Operating Officer Appointment Pulse Biosciences, Inc. has appointed Liane R. Teplitsky as its Chief Operating Officer, effective as of April 8, 2026. Filing
- Apr 7, 2026AnnouncementPulse Biosciences, Inc. issued a press release announcing the first enrollment of patients in its NANOPULSE-AF clinical study, a prospective, multicenter, pivotal, clinical investigation currently evaluating the Company’s nPulse™ Cardiac Catheter System for treating recurrent, drug-resistant… Filing
- Mar 27, 2026LeadershipThe Compensation Committee of the Board of Directors of Pulse Biosciences, Inc. awarded the Company’s Chief Technology Officer, Darrin R. Uecker, for his continued leadership of the Company’s product development efforts for the treatment of atrial fibrillation, a grant of restricted stock units… Filing
- Mar 17, 2026AnnouncementPulse Biosciences, Inc. issued a press release announcing an organizational realignment to support the Company’s increasing focus on developing its nsPFA electrophysiology catheters and other cardiac devices for the treatment of atrial fibrillation. Filing
- Mar 12, 2026AnnouncementPulse Biosciences, Inc. issued a press release announcing the first enrollment of patients in the investigator-sponsored clinical study of its proprietary Vybrance™ Percutaneous Electrode System as a potential treatment for papillary thyroid microcarcinoma, a small, slow-growing, and most common… Filing
- Mar 9, 2026AnnouncementPulse Biosciences, Inc. issued a press release announcing long-term follow-up data from its nPulse™ Vybrance™ Percutaneous Electrode System first-in-human feasibility study. Filing
- Mar 3, 2026AnnouncementShared information with investors. Filing
- Mar 2, 2026LeadershipAmended an earlier report. Kevin P. Danahy, the Chief Commercial Officer of Pulse Biosciences, Inc. gave notice that he was resigning from the Company, effective immediately. Filing
- Feb 27, 2026LeadershipKevin P. Danahy, the Chief Commercial Officer of Pulse Biosciences, Inc. gave notice that he was resigning from the Company, effective immediately. Filing
- Feb 19, 2026ResultsReleased financial results. Filing
- Feb 19, 2026AgreementPulse Biosciences, Inc. entered into an equity distribution agreement with TD Securities (USA) LLC as sales agent, pursuant to which the Company may offer and sell, from time to time, through TD Cowen shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering… Filing
- Feb 6, 2026AnnouncementPulse Biosciences, Inc. issued a press release announcing 6- and 12-month data from its nPulse TM Cardiac Catheter first-in-human feasibility study. Filing
- Jan 14, 2026AnnouncementShared information with investors. Filing
- Jan 9, 2026LeadershipThe Board of Directors of Pulse Biosciences, Inc. elected Maria Sainz to the Board, effective immediately. Filing
- Dec 18, 2025AnnouncementPulse Biosciences, Inc. issued a press release announcing the approval of its Investigational Device Exemption (IDE) submission by the U.S. Food and Drug Administration, allowing the Company to proceed with the initiation of its NANOPULSE-AF clinical study for the treatment of paroxysmal atrial… Filing
- Dec 12, 2025VoteReported shareholder vote results. Filing
- Dec 9, 2025AnnouncementPulse Biosciences, Inc. issued a press release announcing a research collaboration with The University of Texas MD Anderson Cancer Center to examine the use of the Company’s nPulse™ Vybrance™ Percutaneous Electrode System for treatment of thyroid cancers. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Pulse Biosciences financials
Famous investors that hold PLSE
3 of the 50 well-known investors we track reported holding PLSE in their latest 13F filing. The largest position is Ken Griffin's, worth $74.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.48M | $74.1M | 0.0% | +137% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 188,727 | $9.4M | 0.0% | +77% |
| Israel Englander · Millennium Management | Q3 2026 | 141,509 | $7.1M | 0.0% | +502% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Pulse Biosciences, Inc. (PLSE) stock
Who owns the most PLSE stock?
The largest reported owner of Pulse Biosciences, Inc. (PLSE) is BlackRock, Inc., with 2.1% of the company. In total, 107 funds and institutions reported holding PLSE at the end of Q2 2026, together about 17% of the shares. See the largest owners.
Are PLSE insiders buying or selling?
In the last 12 months, PLSE insiders reported 6 open-market purchases worth $13.5M and 7 sales worth $2.9M. The latest trade was on Sep 1, 2026. See every trade.
What is the short interest in PLSE?
As of Oct 30, 2026, 2.90M PLSE shares were sold short, 4.1% of the shares outstanding, down 3.5% from the report before. At the average daily volume of 351,715 shares, buying them all back would take about 8.2 trading days (days to cover). See the history.
Which famous investors hold PLSE?
3 of the 50 well-known investors we track reported PLSE in their latest 13F filing, including Ken Griffin, Steve Cohen, Israel Englander. The largest position is worth $74.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.